Biosimilar medicine authorized by the European Commission
ACTIVE PRINCIPLE: follitropin alfa
INDICATION: Anovulation
DATE: 27/09/2013
STATUS: Authorized
MORE INFORMATION
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
SUBSCRIBE
